PARP inhibitors represent an exciting new class of anticancer agents and are currently being evaluating in phase III for a number of different indications.
John F. Hilton, MD
Advertisement
Articles by John F. Hilton, MD
Advertisement
Latest Updated Articles
PARP Inhibitors for Breast and Ovarian CancersPublished: November 26th 2014 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5